RBC Capital Reiterates Sector Perform on Sage Therapeutics, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a price target of $26.

March 11, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains a 'Sector Perform' rating on Sage Therapeutics with a $26 price target.
The reiteration of the 'Sector Perform' rating and maintenance of the $26 price target by RBC Capital suggests a neutral outlook on Sage Therapeutics. This indicates that the analyst believes the stock is fairly valued at its current level, implying no significant short-term price movement is expected based on this analysis alone.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100